Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Mediar Therapeutics is raising $31,761,186.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Meredith Fisher played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mediar Therapeutics
Drugging the myofibroblast: a new approach to treating fibrosis.

To learn more about Mediar Therapeutics, visit http://www.mediartx.com/

Contact:
Meredith Fisher, Chief Executive Officer
617-954-9356

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved